Retatrutide Achieves 25% Weight Loss in Phase 3 Trial
Retatrutide, a competitor to Ozempic, has demonstrated a 25% weight loss in a Phase 3 clinical trial. This significant result highlights its potential as an effective treatment for obesity, marking a major advancement in weight loss therapies. The trial's success positions Retatrutide as a promising alternative in the pharmaceutical market.
NDTV·



